Entera Bio Ltd. Ordinary Shares earnings per share and revenue
On 14 de nov. de 2025, ENTX reported earnings of -0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 23.75% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -1.11% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.09 USD, with revenue projected to reach -- USD, implying an aumentar of 28.57% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Entera Bio Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Entera Bio Ltd. Ordinary Shares reported EPS of -$0.07, beating estimates by 23.75%, and revenue of --, -- -- expectations.
How did the market react to Entera Bio Ltd. Ordinary Shares's Q3 2025 earnings?
The stock price moved down -1.11%, changed from $2.71 before the earnings release to $2.68 the day after.
When is Entera Bio Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for 26 de mar. de 2026.
What are the forecasts for Entera Bio Ltd. Ordinary Shares's next earnings report?
Based on 3
analistas, Entera Bio Ltd. Ordinary Shares is expected to report EPS of -$0.09 and revenue of -- for Q4 2025.